---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-22-000028"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2022-08-05T23:59:59+00:00"
generated_at: "2026-06-24T03:24:39.270769+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Amneal Q2 2022: net loss $121M, revenue +5% to $559M; Opana settlement charge $263M

## Summary
- Q2 2022 net revenue $559M (+5% YoY); GAAP net loss $121M vs net income $15M in Q2 2021.
- Adjusted EBITDA $135M (-6% YoY); adjusted diluted EPS $0.19 vs $0.23 in prior year.
- Pre-tax charge of $263M for Opana ER antitrust litigation settlement recorded.
- 2022 adjusted EBITDA guidance updated; specific figure not disclosed in provided excerpt.

## SEC filing metadata
- accession: 0001723128-22-000028
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2022-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312822000028/0001723128-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312822000028/amrx-20220805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-22-000028
- JSON: https://secwatch.observer/filing/0001723128-22-000028.json
- Plain text: https://secwatch.observer/filing/0001723128-22-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.